Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saltikva in Metastatic Pancreatic Cancer
NCT04589234Phase 2Active, not recruiting
- Sponsor
- Salspera
- Start
- Oct 2020
- Primary completion
- Dec 2030
- Modality
- Gene Editing, Gene Silencing, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of Saltikva in pancreatic cancer (PC) (2 arms), sponsored by Salspera. Primary endpoints: Overall Survival at 24 months and Progression Free Survival at 24 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
Saltikva
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04589234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589234.